HK Stock MarketDetailed Quotes

01099 SINOPHARM

Watchlist
  • 21.600
  • +0.700+3.35%
Market Closed Apr 24 16:08 CST
67.41BMarket Cap6.75P/E (TTM)

SINOPHARM Key Stats

Earnings

Revenue Breakdown

Financial Indicators

Income Statement

Balance Sheet

Cash Flow

All
YOY yoy
Hide blank lines yoy
(FY)Dec 31, 2023
(Q9)Sep 30, 2023
(Q6)Jun 30, 2023
(Q3)Mar 31, 2023
(FY)Dec 31, 2022
(Q9)Sep 30, 2022
(Q6)Jun 30, 2022
(Q3)Mar 31, 2022
(FY)Dec 31, 2021
(Q9)Sep 30, 2021
Turnover
8.05%596.57B
9.73%445.92B
15.10%300.95B
14.04%145.52B
5.97%552.15B
6.58%406.38B
4.96%261.47B
6.10%127.6B
14.16%521.05B
16.38%381.29B
Operating income
8.05%596.57B
9.73%445.92B
15.10%300.95B
14.04%145.52B
5.97%552.15B
6.58%406.38B
4.96%261.47B
6.10%127.6B
14.16%521.05B
16.38%381.29B
Cost of sales
-8.59%-548.06B
----
-15.79%-277.68B
----
-5.81%-504.71B
----
-4.94%-239.81B
----
-14.64%-477B
----
Operating expenses
-8.59%-548.06B
-10.31%-410.72B
-15.79%-277.68B
-14.45%-134.58B
-5.81%-504.71B
-6.74%-372.34B
-4.94%-239.81B
-5.89%-117.59B
-14.64%-477B
-16.72%-348.81B
Gross profit
2.27%48.51B
3.38%35.2B
7.45%23.27B
9.30%10.94B
7.68%47.43B
4.85%34.05B
5.20%21.66B
8.58%10.01B
9.24%44.05B
12.91%32.47B
Selling expenses
-4.50%-17.47B
-6.12%-12.65B
-8.44%-8.43B
-8.87%-4.13B
-8.30%-16.72B
-2.18%-11.92B
-2.26%-7.78B
-1.13%-3.8B
-9.16%-15.44B
-18.40%-11.66B
Administrative expenses
-6.04%-8.68B
-5.90%-5.48B
-8.43%-3.97B
-7.15%-1.74B
-5.44%-8.18B
-5.70%-5.18B
-6.33%-3.66B
-5.04%-1.62B
-10.09%-7.76B
-10.07%-4.9B
Research and development expenses
----
-23.96%-260.77M
----
-55.73%-95.96M
----
-66.90%-210.37M
----
-45.83%-61.62M
----
-29.62%-126.04M
Profit from asset sales
-6.80%-2.07B
1,278.98%322.01M
----
545.49%23.3M
-71.22%-1.94B
-52.87%23.35M
----
-91.67%3.61M
11.21%-1.13B
925.80%49.55M
Revaluation surplus
----
-101.34%-102.82K
----
-100.75%-58.58K
----
4,508,976.74%7.67M
----
31,179.01%7.76M
----
-98.15%170
-Changes in the fair value of other assets
----
-101.34%-102.82K
----
-100.75%-58.58K
----
4,508,976.74%7.67M
----
31,179.01%7.76M
----
-98.15%170
Impairment and provision
-0.07%-666.97M
-21.28%-1.62B
-30.58%-1.29B
-40.08%-787.55M
-11.36%-666.47M
-39.64%-1.34B
-38.99%-987.6M
-17.48%-562.2M
20.23%-598.48M
28.49%-959.48M
-Other impairment is provision
-0.07%-666.97M
-21.28%-1.62B
-30.58%-1.29B
-40.08%-787.55M
-11.36%-666.47M
-39.64%-1.34B
-38.99%-987.6M
-17.48%-562.2M
20.23%-598.48M
28.49%-959.48M
Special items of operating profit
-13.92%582.01M
42.78%574.7M
101.04%1.82M
77.82%293.38M
14.76%676.16M
-33.62%402.52M
-205.35%-175.83M
-30.51%164.99M
-9.63%589.19M
58.10%606.34M
Operating profit
-1.92%20.21B
1.56%15.07B
5.79%9.58B
9.36%4.19B
4.53%20.6B
2.03%14.84B
3.25%9.06B
12.30%3.84B
10.99%19.71B
15.21%14.55B
Financing income
36.96%743.37M
----
9.77%350.3M
----
-2.83%542.77M
----
1.80%319.13M
----
-17.07%558.56M
----
Financing cost
14.98%-3.17B
10.00%-2.03B
7.11%-1.77B
18.79%-560.15M
5.77%-3.73B
3.26%-2.25B
-0.25%-1.9B
-8.60%-689.75M
-9.42%-3.96B
-22.67%-2.33B
Share of profits of associates
4.46%1.11B
----
16.39%571.3M
----
-0.47%1.06B
----
8.04%490.85M
----
8.48%1.07B
----
Share of profit from joint venture company
-244.88%-4.22M
----
46.72%2.98M
----
318.99%2.91M
----
239.87%2.03M
----
-63.44%695K
----
Special items of earning before tax
660.80%625.97M
-2,740.26%-19.47M
236.55%128.2M
-14.76%3.77M
121.89%82.28M
-96.94%737.47K
-49.38%38.09M
-55.72%4.42M
-85.75%-375.81M
1,215.56%24.08M
Earning before tax
5.11%19.51B
3.47%13.03B
10.77%8.87B
15.49%3.64B
9.18%18.56B
2.85%12.59B
3.72%8B
12.90%3.15B
9.01%17B
14.09%12.24B
Tax
-6.73%-4.5B
-6.55%-2.96B
-11.14%-1.97B
-14.72%-827.84M
-7.11%-4.22B
-1.95%-2.78B
-5.13%-1.78B
-14.68%-721.61M
-12.50%-3.94B
-11.79%-2.72B
After-tax profit from continuing operations
4.63%15.01B
2.60%10.07B
10.67%6.89B
15.72%2.81B
9.80%14.35B
3.10%9.81B
3.32%6.23B
12.38%2.43B
8.00%13.06B
14.77%9.52B
Earning after tax
4.63%15.01B
2.60%10.07B
10.67%6.89B
15.72%2.81B
9.80%14.35B
3.10%9.81B
3.32%6.23B
12.38%2.43B
8.00%13.06B
14.77%9.52B
Minority profit
2.34%5.96B
0.39%3.97B
10.02%2.79B
21.91%1.22B
9.68%5.82B
3.66%3.96B
3.65%2.53B
5.91%1B
8.07%5.31B
14.46%3.82B
Adjustment items of profit attributable to shareholders
----
----
----
----
----
---0.01
----
----
----
----
Profit attributable to shareholders
6.19%9.05B
4.09%6.1B
11.12%4.1B
11.38%1.59B
9.89%8.53B
2.73%5.86B
3.10%3.69B
17.41%1.43B
7.95%7.76B
14.98%5.7B
Basic earnings per share
6.23%2.9
4.26%1.96
11.86%1.32
10.87%0.51
9.64%2.73
2.73%1.88
2.61%1.18
17.95%0.46
7.79%2.49
10.24%1.83
Diluted earnings per share
6.23%2.9
4.26%1.96
11.86%1.32
10.87%0.51
9.64%2.73
2.73%1.88
2.61%1.18
17.95%0.46
7.79%2.49
10.24%1.83
Currency Unit
CNY
CNY
CNY
CNY
CNY
CNY
CNY
CNY
CNY
CNY
Accounting Standards
HKAS
CAS (2007)
HKAS
CAS (2007)
HKAS
CAS (2007)
HKAS
CAS (2007)
HKAS
CAS (2007)
Audit Opinions
Unqualified Opinion
--
--
--
Unqualified Opinion
--
--
--
Unqualified Opinion
--
Auditor
PricewaterhouseCoopers, PricewaterhouseCoopers Zhongtian (Special General Partnership)
--
--
--
Ernst & Young Huaming (Special General Partnership), Ernst & Young
--
--
--
Ernst & Young Huaming (Special General Partnership), Ernst & Young
--
(FY)Dec 31, 2023(Q9)Sep 30, 2023(Q6)Jun 30, 2023(Q3)Mar 31, 2023(FY)Dec 31, 2022(Q9)Sep 30, 2022(Q6)Jun 30, 2022(Q3)Mar 31, 2022(FY)Dec 31, 2021(Q9)Sep 30, 2021
Turnover 8.05%596.57B9.73%445.92B15.10%300.95B14.04%145.52B5.97%552.15B6.58%406.38B4.96%261.47B6.10%127.6B14.16%521.05B16.38%381.29B
Operating income 8.05%596.57B9.73%445.92B15.10%300.95B14.04%145.52B5.97%552.15B6.58%406.38B4.96%261.47B6.10%127.6B14.16%521.05B16.38%381.29B
Cost of sales -8.59%-548.06B-----15.79%-277.68B-----5.81%-504.71B-----4.94%-239.81B-----14.64%-477B----
Operating expenses -8.59%-548.06B-10.31%-410.72B-15.79%-277.68B-14.45%-134.58B-5.81%-504.71B-6.74%-372.34B-4.94%-239.81B-5.89%-117.59B-14.64%-477B-16.72%-348.81B
Gross profit 2.27%48.51B3.38%35.2B7.45%23.27B9.30%10.94B7.68%47.43B4.85%34.05B5.20%21.66B8.58%10.01B9.24%44.05B12.91%32.47B
Selling expenses -4.50%-17.47B-6.12%-12.65B-8.44%-8.43B-8.87%-4.13B-8.30%-16.72B-2.18%-11.92B-2.26%-7.78B-1.13%-3.8B-9.16%-15.44B-18.40%-11.66B
Administrative expenses -6.04%-8.68B-5.90%-5.48B-8.43%-3.97B-7.15%-1.74B-5.44%-8.18B-5.70%-5.18B-6.33%-3.66B-5.04%-1.62B-10.09%-7.76B-10.07%-4.9B
Research and development expenses -----23.96%-260.77M-----55.73%-95.96M-----66.90%-210.37M-----45.83%-61.62M-----29.62%-126.04M
Profit from asset sales -6.80%-2.07B1,278.98%322.01M----545.49%23.3M-71.22%-1.94B-52.87%23.35M-----91.67%3.61M11.21%-1.13B925.80%49.55M
Revaluation surplus -----101.34%-102.82K-----100.75%-58.58K----4,508,976.74%7.67M----31,179.01%7.76M-----98.15%170
-Changes in the fair value of other assets -----101.34%-102.82K-----100.75%-58.58K----4,508,976.74%7.67M----31,179.01%7.76M-----98.15%170
Impairment and provision -0.07%-666.97M-21.28%-1.62B-30.58%-1.29B-40.08%-787.55M-11.36%-666.47M-39.64%-1.34B-38.99%-987.6M-17.48%-562.2M20.23%-598.48M28.49%-959.48M
-Other impairment is provision -0.07%-666.97M-21.28%-1.62B-30.58%-1.29B-40.08%-787.55M-11.36%-666.47M-39.64%-1.34B-38.99%-987.6M-17.48%-562.2M20.23%-598.48M28.49%-959.48M
Special items of operating profit -13.92%582.01M42.78%574.7M101.04%1.82M77.82%293.38M14.76%676.16M-33.62%402.52M-205.35%-175.83M-30.51%164.99M-9.63%589.19M58.10%606.34M
Operating profit -1.92%20.21B1.56%15.07B5.79%9.58B9.36%4.19B4.53%20.6B2.03%14.84B3.25%9.06B12.30%3.84B10.99%19.71B15.21%14.55B
Financing income 36.96%743.37M----9.77%350.3M-----2.83%542.77M----1.80%319.13M-----17.07%558.56M----
Financing cost 14.98%-3.17B10.00%-2.03B7.11%-1.77B18.79%-560.15M5.77%-3.73B3.26%-2.25B-0.25%-1.9B-8.60%-689.75M-9.42%-3.96B-22.67%-2.33B
Share of profits of associates 4.46%1.11B----16.39%571.3M-----0.47%1.06B----8.04%490.85M----8.48%1.07B----
Share of profit from joint venture company -244.88%-4.22M----46.72%2.98M----318.99%2.91M----239.87%2.03M-----63.44%695K----
Special items of earning before tax 660.80%625.97M-2,740.26%-19.47M236.55%128.2M-14.76%3.77M121.89%82.28M-96.94%737.47K-49.38%38.09M-55.72%4.42M-85.75%-375.81M1,215.56%24.08M
Earning before tax 5.11%19.51B3.47%13.03B10.77%8.87B15.49%3.64B9.18%18.56B2.85%12.59B3.72%8B12.90%3.15B9.01%17B14.09%12.24B
Tax -6.73%-4.5B-6.55%-2.96B-11.14%-1.97B-14.72%-827.84M-7.11%-4.22B-1.95%-2.78B-5.13%-1.78B-14.68%-721.61M-12.50%-3.94B-11.79%-2.72B
After-tax profit from continuing operations 4.63%15.01B2.60%10.07B10.67%6.89B15.72%2.81B9.80%14.35B3.10%9.81B3.32%6.23B12.38%2.43B8.00%13.06B14.77%9.52B
Earning after tax 4.63%15.01B2.60%10.07B10.67%6.89B15.72%2.81B9.80%14.35B3.10%9.81B3.32%6.23B12.38%2.43B8.00%13.06B14.77%9.52B
Minority profit 2.34%5.96B0.39%3.97B10.02%2.79B21.91%1.22B9.68%5.82B3.66%3.96B3.65%2.53B5.91%1B8.07%5.31B14.46%3.82B
Adjustment items of profit attributable to shareholders -----------------------0.01----------------
Profit attributable to shareholders 6.19%9.05B4.09%6.1B11.12%4.1B11.38%1.59B9.89%8.53B2.73%5.86B3.10%3.69B17.41%1.43B7.95%7.76B14.98%5.7B
Basic earnings per share 6.23%2.94.26%1.9611.86%1.3210.87%0.519.64%2.732.73%1.882.61%1.1817.95%0.467.79%2.4910.24%1.83
Diluted earnings per share 6.23%2.94.26%1.9611.86%1.3210.87%0.519.64%2.732.73%1.882.61%1.1817.95%0.467.79%2.4910.24%1.83
Currency Unit CNYCNYCNYCNYCNYCNYCNYCNYCNYCNY
Accounting Standards HKASCAS (2007)HKASCAS (2007)HKASCAS (2007)HKASCAS (2007)HKASCAS (2007)
Audit Opinions Unqualified Opinion------Unqualified Opinion------Unqualified Opinion--
Auditor PricewaterhouseCoopers, PricewaterhouseCoopers Zhongtian (Special General Partnership)------Ernst & Young Huaming (Special General Partnership), Ernst & Young------Ernst & Young Huaming (Special General Partnership), Ernst & Young--

FY: Financial Year. Refers to the 10-K file disclosed by the listed company to the SEC.

Q: Quarter. Refers to the 10-Q file disclosed by the listed company to the SEC. Q1, Q2, Q3, and Q4 are quarterly reports each with a span of 3 months; Q6 and Q9 are cumulative reports, with Q6 including 6 months and Q9 9 months.

Analysis

Analyst Rating

No Data

Price Target

No Data

Heat List
HK
Overall
Symbol
Latest Price
%Chg